Carolina Specialty Oncology (“CSO” or the “Company”), a provider of comprehensive cancer treatment services, has been acquired by UNC Rex Healthcare.

As the largest regional independent cancer treatment provider in North Carolina, CSO specializes in cancer care for patients with urological as well as head and neck cancers. Through its specialization, CSO is able to offer the very best in cancer care for its patients using the latest equipment and technology combined with a state of the art facility, specially trained staff and highly customized patient treatment programs.

The Company’s unique approach to oncology brings together all stake holders in patient care, creating a seamless collaboration between the patient, radiation oncologists, referring physicians and associated medical practices that provide other surgery and medical oncology treatments. As part of its comprehensive offering, CSO also offers related ancillary services including rehabilitation, nutrition and counseling.

UNC Rex Healthcare is a private, non-profit regional healthcare system serving the greater Raleigh-Durham-Chapel Hill metropolitan area of North Carolina and was highlighted as one of the Top 50 Hospitals in the U.S. by Becker’s Hospital Review. CSO will become a part of the UNC Rex Healthcare Cancer Care division.

Philpott Ball & Werner, LLC (“PB&W”) served as exclusive investment banker to CSO. Terms of the transaction were not disclosed. For more information about this transaction, please contact Matthew Carpenter at